Virtual Library
Start Your Search
Ignacio Wistuba
Author of
-
+
IASLC Pre-Conference School of Pathology (ID 4)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2019, 08:15 - 15:30, Feria 2-3
-
+
PC4.03 - Major Pathological Response in Lung Cancer Neoadjuvant-Therapy (ID 43)
08:15 - 15:30 | Author(s): Ignacio Wistuba
- Abstract
Abstract not provided
-
+
Session 3: 2019 American Society of Clinical Oncology (ASCO) / IASLC Symposia: Lung Cancer Pathology in the Era of Targeted Therapy (ID 15)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2019, 10:30 - 11:30, Castillo A 1-4
-
+
F3.02 - New Massive Parallel Sequencing Platforms (NGS) Versus Tailored Panels (ddPCR) (ID 73)
10:30 - 11:30 | Author(s): Ignacio Wistuba
- Abstract
Large scale application of this technology in tumor molecular characterization of lung cancer led to the generation of databases that catalog the next generation of sequencing (NGS) tumor genome. Several NGS platforms and assays have been developed and applied in the clinical setting to genotyping of tumor for targeted therapy, including lung non-small cell carcinoma (NSCLC). These NGS platforms have all the features required to carry out simultaneous analysis of a large number of genes (hot-spots and exomes) with actionable alterations (mutations, copy number changes and translocation) in tumor tissue, and thus providing a more precise molecular characterization of the tumor. Such targeted NGS panels for somatic aberrations detection, include actionable lung cancer genes (100-400 genes) aiming to increase the percentage of patients with detectable actionable somatic gene alterations that can be used to guide treatment decision in standard of care and clinical trial settings. Importantly, these NGS panels can be applied to clinically relevant tumor biopsies (formalin-fixed and paraffin-embedded tissues and cytology specimens), and cell freed DNA samples (liquid biopsy). In summary, NGS panels have the following benefits in lung cancer: a) Provide information in multiple targetable gene abnormalities; b) data on actionable mutation, copy number variations, indels and translocations; c) can be performed in routine small FFPE tissue samples and liquid biopsy (cfDNA); d) turn-around time acceptable for clinical management and costs being significantly reduced; e) clinically, it offers to patients more options to get off-label treatment and enter in genomic-based clinical trials; and, f) may provide information on tumor mutational burden (TMB) and other potential genomic-based immune-suppressive genotypes (e.g., LKB1 mutations). Although NGS panels are preferred, there are other more cost effective genotyping platforms that can provide information on the minimal set of genes abnormalities (EGFR, ALK, MET, ROS1, BRAF, NTRK) required for the proper management of NSCLC patients testing panels of gene hot-spot abnormalities using quantitative (q)PCR and digital droplet (dd)PCR methodologies. The integration right genotyping testing multi-gene panels in lung cancer management of patients is of great clinical importance, as well as the selection of the right platform for each clinical setting.
